RESEARCH PROFILEClinical neuroscience, neuropsychopharmacology, cognitive neuroscience, psychosis, prodromal psychosis, affective disorders, psychopathology, neuroimaging, fMRI, EEG, resting-state, connectivity, computational neuroscience, biological psychiatry, biological marker.
BACKGROUNDDr. sc. nat. André Schmidt studied neuroscience at the ETH in Zurich. He completed his Ph.D. at the University Hospital of Psychiatry in Zurich working on electro-pharmacological models of psychosis with the aim to study pathophysiological mechanisms of specific symptom formation, in particular of cognitive impairments. Currently, André Schmidt works as a post-doc at the University Hospital of Psychiatry in Basel with a research focus on sophisticated connectivity analyses of resting-state and functional imaging data implicated in diverse psychiatric diseases.
CURRENT RESEARCH PROJECTSMultimodal imaging of the psychosis high-risk state. In different working projects, we try to find robust neuronal correlates underlying the onset of psychosis by using structural and functional magnetic resonance imaging measurements and computational modeling approaches during a variety of cognitive and emotional paradigms.
Resting-state fMRI analysis. I am working in different projects evaluating regional brain interactions during rest, i.e., without any task. In particular, we study how resting-state brain connectivity changes after pharmacological manipulations and physical training, as well as in different psychiatric diseases.
The neurobiology of drug addiction. In these research projects, we investigate how neuronal structures, functional brain activity and behavior are changed as a result of drug consumption.
Brain connectivity abnormalities predating the onset of psychosis: correlation with the effect of medication.
Schmidt, A, Smieskova R, Aston, J, Simon A, Allen P, Fusar-Poli P, McGuire PK, Riecher-Rössler A, Stephan KE, Borgwardt S. Archives of General Psychiatry/JAMA Psychiatry. 2013. In press.
Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.
Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, Vollenweider FX (2012). Neuropsychopharmacology 37:865-75.
Modeling Ketamine Effects on Synaptic Plasticity During the Mismatch Negativity.
Schmidt A, Diaconescu AO, Kometer M, Friston KJ, Stephan KE, Seifritz E, Vollenweider FX (2012). Cerebral Cortex doi: 10.1093/cercor/bhs238
The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.
Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider FX (2012). Psychopharmacology doi: 10.1007/s00213-012-2811-0.
Psilocybin biases facial recognition, goal-directed behavior, and mood state towards positive relative to negative emotions through different serotonergic subreceptors.
Kometer M, Schmidt A, Bachmann R, Vollenweider FX (2012). Biological Psychiatry 72:898-906.
Molecular Bases Of Antipsychotic Drugs: The Contribution Of Neurosciences.
Borgwardt S, Schmidt A (2012). Current Medical Chemistry, in press.
Do subjects at clinical high risk for psychosis differ from those with a genetic high risk? – A systematic review of structural and functional brain abnormalities.
Smieskova R, Fusar-Poli P, Marmy J, Schmidt A, Bendfeldt K, Riecher-Rössler A, Walter M, Lang UE, Borgwardt S (2012). Current Medical Chemistry, in press.